TEL AVIV, Israel, Jan. 16, 2018 /PRNewswire/ -- Cellect
Biotechnology Ltd. (Nasdaq: APOP), a developer of a novel stem cell
selection technology, announced that it has signed an agreement
with the Hadassah Medical Center to conduct clinical trials on
cancer patients in Cellect's ongoing Phase I/II study. The study at
Hadassah will be conducted under Prof. Polina Stefenski, the
Principal Investigator of the site at Hadassah. Furthermore,
following the recently announced positive interim results in the
Phase I/II clinical trial with the first group of patients treated
at the Rambam Medical Center, Cellect received approval from the
independent Data and Safety Monitoring Board (DSMB) to escalate
ApoGraft™ FasL protein dosage (Cellect's main active ingredient in
ApoGraft™) to 25 ng/ml and enroll three additional patients for the
clinical trial.
Dr. Shai Yarkoni, Cellect's CEO
said, "Stem cells are the key raw material for the emergence of
Cell Therapy into the 21st century as the new standard
for well-being. We believe Cellect's innovative technology paves
the way to make sure quality stem cells are available for mass
usage on a global basis."
About Regenerative Medicine and Cell Therapy
Regenerative medicine is a novel approach using cells and
tissues to replace or regenerate human cells, tissues or organs in
a wide variety of medical indications. This could be achieved by
either stimulating the body to use its own repair mechanisms to
heal tissues or organs, or by growing tissues and organs in the
laboratory and transplanting them into the patient.
Stem cells play a major role in the achievement of the
extraordinary potential results in regenerative medicine. In cell
therapies they can be injected to reconstitute the entire blood
system in bone marrow transplantations. Alternatively, their
injection can supply the necessary biologically active molecules to
induce the patients' own cells to regain normal function, as used
in immunomodulation therapy. In tissue engineering, where entire
organs like the retina, bone, cartilage or the skin may be
replaced, stem cells are the starting material for the growth of
such tissues in the laboratory. Moreover, in tissue engineering an
artificial system might be created by inducing cells to perform
certain biochemical functions lost due to disease (e.g., artificial
pancreas or liver).
Regenerative medicine using cellular therapy in combination with
new technologies like tissue engineering and gene transfer can be
used in a virtually unlimited number of indications. The most
frequently used cells are hematopoietic stem cells (HSC) due to
their capability to reproduce the entire blood system in blood
cancer and hematological disorders. Mesenchymal stem cells, which
have the capability to differentiate to a large number of tissue
types like bone, cartilage, fat, heart muscle and more, are of
growing importance with a large number of clinical trials ongoing.
Potential applications of cell therapies include treating cancers,
autoimmune disease, urinary problems and infectious disease,
rebuilding damaged cartilage in joints, repairing spinal cord
injuries, improving a weakened immune system, and helping patients
with neurological disorders.
About Cellect Biotechnology Ltd.
Cellect Biotechnology (NASDAQ: APOP) has developed a
breakthrough technology for the selection of stem cells from any
given tissue that aims to improve a variety of stem cell-based
therapies.
The Company's technology is expected to provide research,
hospitals and pharma companies with the tools to rapidly isolate
stem cells in quantity and quality allowing stem cell-based
treatments and procedures in a wide variety of applications in
regenerative medicine. The current clinical trial is aimed at bone
marrow transplantations in cancer treatment.
Forward Looking Statements
This press release contains forward-looking statements about the
Company's expectations, beliefs and intentions. Forward-looking
statements can be identified by the use of forward-looking words
such as "believe", "expect", "intend", "plan", "may", "should",
"could", "might", "seek", "target", "will", "project", "forecast",
"continue" or "anticipate" or their negatives or variations of
these words or other comparable words or by the fact that these
statements do not relate strictly to historical matters. For
example, forward-looking statements are used in this press release
when we discuss Cellect's intent regarding the effects of the
ApoGraft™ transplantation and Cellect's aims and expectations
regarding the future of its ApoGraft™ technology and stem cell
based regenerative medicine. These forward-looking statements and
their implications are based on the current expectations of the
management of the Company only, and are subject to a number of
factors and uncertainties that could cause actual results to differ
materially from those described in the forward-looking statements.
In addition, historical results or conclusions from procedures,
scientific research and clinical studies do not guarantee that
future results would suggest similar conclusions or that historical
results referred to herein would be interpreted similarly in light
of additional research or otherwise. The following factors, among
others, could cause actual results to differ materially from those
described in the forward-looking statements: changes in technology
and market requirements; we may encounter delays or obstacles in
launching and/or successfully completing our clinical trials; our
products may not be approved by regulatory agencies, our technology
may not be validated as we progress further and our methods may not
be accepted by the scientific community; we may be unable to retain
or attract key employees whose knowledge is essential to the
development of our products; unforeseen scientific difficulties may
develop with our process; our products may wind up being more
expensive than we anticipate; results in the laboratory may not
translate to equally good results in real clinical settings;
results of preclinical studies may not correlate with the results
of human clinical trials; our patents may not be sufficient; our
products may harm recipients; changes in legislation; inability to
timely develop and introduce new technologies, products and
applications, which could cause the actual results or performance
of the Company to differ materially from those contemplated in such
forward-looking statements. Any forward-looking statement in this
press release speaks only as of the date of this press release. The
Company undertakes no obligation to publicly update or review any
forward-looking statement, whether as a result of new information,
future developments or otherwise, except as may be required by any
applicable securities laws. More detailed information about the
risks and uncertainties affecting the Company is contained under
the heading "Risk Factors" in Cellect Biotechnology Ltd.'s Annual
Report on Form 20-F for the fiscal year ended December 31, 2016 filed with the U.S. Securities
and Exchange Commission, or SEC, which is available on the SEC's
website, www.sec.gov and in the Company's period filings with the
SEC.
Contact
Cellect Biotechnology Ltd.
Eyal Leibovitz, Chief Financial
Officer
www.cellect.co
+972-9-974-1444
View original
content:http://www.prnewswire.com/news-releases/cellect-announces-opening-of-a-second-clinical-trial-site-and-approval-from-safety-board-dsmb-for-dose-escalation-300583005.html
SOURCE Cellect Biotechnology Ltd.